MVA-BN-RSV

BIOLOGICAL2 trials

Sponsors

Bavarian Nordic

Conditions

Respiratory Syncytial Virus Infections

Phase 1

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

WithdrawnNCT02864628

Bavarian NordicRespiratory Syncytial Virus Infections

Start: 2016-09-30End: 2017-10-27Updated: 2018-08-27

Phase 2

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

CompletedNCT02873286

Bavarian NordicRespiratory Syncytial Virus Infections

Start: 2016-09-30End: 2018-12-31Updated: 2020-09-22

Related Papers

Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine

The Journal of Infectious Diseases2020-07-2460 citations